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We investigated the azole resistance mechanisms and clinical features of fluconazole-nonsusceptible (FNS) isolates of Candida
tropicalis recovered fromKorean surveillance cultures in comparison with fluconazole-less-susceptible (FLS) isolates. Thirty-
five clinical isolates of C. tropicalis, comprising 9 FNS (fluconazole MIC, 4 to 64g/ml), 12 FLS (MIC, 1 to 2g/ml), and 14 con-
trol (MIC, 0.125 to 0.5g/ml) isolates, were assessed. CDR1,MDR1, and ERG11 expression was quantified, and the ERG11 and
UPC2 genes were sequenced. Clinical features of 16 patients with FNS or FLS bloodstream isolates were analyzed. Both FNS and
FLS isolates had>10-fold higher mean expression levels of CDR1,MDR1, and ERG11 genes than control isolates (P values
of<0.02 for all). When FNS and FLS isolates were compared, FNS isolates had 3.4-fold higher mean ERG11 expression levels
than FLS isolates (P 0.004), but there were no differences in those of CDR1 orMDR1. Of all 35 isolates, 4 (2 FNS and 2 FLS)
and 28 (8 FNS, 11 FLS, and 9 control) isolates exhibited amino acid substitutions in Erg11p and Upc2p, respectively. Both FNS
and FLS bloodstream isolates were associated with azole therapeutic failure (3/4 versus 4/7) or uncleared fungemia (4/6 versus
4/10), but FNS isolates were identified more frequently from patients with previous azole exposure (6/6 versus 3/10; P 0.011)
and immunosuppression (6/6 versus 3/10; P 0.011). These results reveal that the majority of FNS C. tropicalis isolates show
overexpression of CDR1,MDR1, and ERG11 genes, and fungemia develops after azole exposure in patients with
immunosuppression.
Candida tropicalis has become an important cause of blood-stream infections (BSIs) in seriously ill patients (1–3). Al-
though C. tropicalis is usually susceptible to azole antifungals, 7 to
40% of clinical isolates have recently been reported to be resistant
to azoles, particularly fluconazole (2–5). The mechanisms respon-
sible for acquired azole resistance are well-characterized in Can-
dida albicans and include mutations in the ERG11 gene, which
encodes the drug target enzyme (lanosterol 14-demethylase),
overexpression of ERG11, and overexpression of genes encoding
efflux pumps (6). In C. tropicalis, overexpression of ERG11 asso-
ciated with missense mutations has been described as the most
frequent azole resistance mechanism in clinical isolates (7, 8).
However, the azole resistance mechanisms of C. tropicalis remain
a matter of debate, and only five studies have been reported to date
(7–11). In addition, there is a lack of substantial research on mu-
tations in the transcription factor Upc2p ofC. tropicalis, which can
induce ERG11 overexpression and contribute to the development
of fluconazole resistance in C. albicans (12–14).
Fluconazole MIC distributions of wild-type C. tropicalis
ranged from 0.125 to 64g/ml following 24 h of incubation using
the Clinical and Laboratory Standards Institute (CLSI) broth mi-
crodilution (BMD) methods, and their modal MIC values were
0.125 to 0.5 g/ml (6). Recently, the CLSI established a C. tropi-
calis species-specific clinical breakpoint for fluconazole (suscepti-
ble, MIC of 2 g/ml) which is identical to the epidemiological
cutoff (MIC, 2 g/ml) (6, 15). In this study, we investigated the
azole resistance mechanisms, genotypes, and clinical features of
fluconazole-nonsusceptible (FNS) isolates (fluconazole MIC,4
g/ml) recovered from Korean surveillance cultures in compari-
son with fluconazole-less-susceptible (FLS) isolates (fluconazole
MIC, 1 to 2 g/ml) or fluconazole-susceptible control isolates
(fluconazole MIC, 0.125 to 0.5g/ml).CDR1,MDR1, and ERG11
expression levels in all isolates were quantified by real-time PCR,
and ERG11 sequencing and multilocus sequence typing (MLST)
were performed. For the first time, we investigated the amino acid
substitutions in Upc2p of these isolates and assessed their associ-
ations with azole resistance. In addition, the clinical features of C.
tropicalis fungemia caused by FNS isolates were compared with
those of FLS isolates.
MATERIALS AND METHODS
C. tropicalis isolates and antifungal susceptibility testing. A total of 35
nonduplicate clinical isolates ofC. tropicalis, which comprised 9 FNS (flu-
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conazole MIC, 4 to 64 g/ml), 12 FLS (fluconazole MIC, 1 to 2 g/ml),
and 14 control (fluconazole MIC, 0.125 to 0.5 g/ml) isolates, were as-
sessed. Twenty-one FNS and FLS isolates were recovered from eight Ko-
rean university hospitals during performance of nationwide surveillance
in Korea (2003 to 2013) (16, 17) and were obtained from blood (n 16),
urine (n  3), ear pus (n  1), and nasal swab (n  1). All 14 control
isolates were obtained from blood cultures. In vitro antifungal suscepti-
bility testing for fluconazole, voriconazole, itraconazole, posaconazole,
amphotericin B, anidulafungin, and micafungin was performed on all
isolates using the BMD method of the CLSI according to document
M27-3; MIC values were determined after 24 h of incubation (18). The
categorical antifungal MICs determined by the CLSI BMD method were
determined based on the new species-specific CLSI clinical breakpoints
(fluconazole, voriconazole, anidulafungin, and micafungin) or epidemi-
ological cutoff values (ECVs; itraconazole, posaconazole, and amphoter-
icin B) forC. tropicalis (15, 19). In addition, the fluconazole and voricona-
zole susceptibilities of all isolates were determined using the Vitek 2
system (AST-YS07 card; bioMérieux, Marcy l’Etoile, France) according to
the manufacturer’s instructions. Quality control was performed by testing
C. krusei ATCC 6258 and C. parapsilosis ATCC 22019.
Quantification of CDR1,MDR1, and ERG11 expression. Total RNA
extraction and real-time reverse transcription-PCR (RT-PCR) for the
evaluation of overexpression of CDR1, MDR1, and ERG11 were per-
formed using methods described previously (7, 8). RNA was extracted
from each isolate using the RNeasy plant minikit (Qiagen Inc., Valencia,
CA, USA) according to the manufacturer’s recommendations. Total RNA
was quantified using a Synergy H1 Microplate Reader (Biotek, Winooski,
VT, USA) and reverse transcribed to cDNA using a first-strand cDNA
synthesis kit (Invitrogen, Carlsbad, CA, USA). Quantitative PCR ofACT1,
CDR1, MDR1, and ERG11 was performed in triplicate as technical repli-
cates using the QuantiTect SYBR green PCR kit (Qiagen, Hilden, Ger-
many) and a Rotor-Gene 3000 (Corbett Research, Sydney, Australia). The
primers used for real-time RT-PCR were described previously (7, 8). Am-
plification conditions consisted of 10 min of denaturation at 95°C, fol-
lowed by 40 cycles of 15 s at 95°C for denaturation, 11 s at 54°C for
annealing, and 22 s at 72°C for elongation. The cycle threshold (CT) value
of the gene was normalized to that of ACT1 (internal control) as a CT
value. Relative gene expression (CT) was calculated as the fold change
in expression of the isolates compared to the mean expression values in 14
control strains with fluconazole MICs of 0.125 to 0.5 g/ml (set to 1.0).
Sequence analysis of ERG11 and UPC2. C. tropicalis genomic DNA
was extracted as described previously (7) and was used as the template for
amplification of the full-length ERG11 and UPC2 genes. Genomic DNA
was extracted from each isolate using the DNeasy plant minikit (Qiagen
Inc., Valencia, CA, USA) and used as the template for PCR amplification.
The primers used for amplification and sequencing of ERG11 were de-
scribed previously (7). Amplification conditions consisted of 5 min of
denaturation at 94°C, followed by 30 cycles of 40 s at 94°C for denatur-
ation, 1 min at 50°C for annealing, and 50 s at 72°C for elongation, and a
final elongation step of 10 min at 72°C. PCR products were purified using
a PCR purification kit (GeneAll) according to the manufacturer’s recom-
mendations. PCR products were sequenced using the above-mentioned
PCR primer pairs. Sequencing of both strands was performed using an
ABI Prism 3130xl genetic analyzer (Applied Biosystems, Foster City, CA,
USA). Nucleotide sequences were analyzed using the MegAlign software
package (DNAStar, Inc., Lasergene, Madison, WI, USA) and compared
with those of C. tropicalis ERG11 ATCC 750 (GenBank accession number
M23673). Newly designed primers were used for amplification and se-
quencing of UPC2: for amplification, 5=-CCACTACCATCACTATC
ATCAC-3= (CtUPC2-F1) and 5=-CAATACCTATTGTGATTACT
TC-3= (CtUPC2-R3); for sequencing, 5=-TCAGAAGCTAATGGCCCA-3=
(CtUPC2-F5), 5=-GGATATTCATCTTGGCAGC-3= (CtUPC2-R5), 5=-
ACCCCTACATCCATTCCA-3= (CtUPC2-F4), 5=-CACGCAATAATCG
CAAGG-3= (CtUPC2-R6), and 5=-CAATACCTATTGTGATTACTTC-3=
(CtUPC2-R3). Amplification conditions were 5 min of denaturation at
94°C, followed by 32 cycles of 30 s at 94°C for denaturation, 90 s at 56°C
for annealing, and 3 min at 72°C for elongation, and a final elongation step
of 10 min at 72°C. Purification and sequencing of PCR products were
performed by the same method as that used for ERG11 sequencing. Nu-
cleotide sequences were analyzed using the MegAlign software package
(DNAStar, Inc.) and compared with that of C. tropicalis (ATCC MYA-
3404).
MLST analysis. The 35 C. tropical isolates were typed using an MLST
scheme described previously (20). The internal regions of six housekeep-
ing genes (ICL1, MDR1 SAPT2, SAPT4, XYR1, and ZWF1a) were se-
quenced. Sequence analysis of both strands was performed using an ABI
Prism 3130xl genetic analyzer (Applied Biosystems). Each strain was char-
acterized as a diploid sequence type (DST), which was the combination of
the genotypes of the six loci. MLST data have been deposited in the MLST
database (http://pubmlst.org/).
Clinical data analysis. Clinical information of 16 fungemic patients
from whom FNS and FLS BSI isolates of C. tropicalis were obtained was
collected retrospectively and included patient demographics, clinical di-
agnosis, antifungal therapy, and outcome of fungemia (21). Therapeutic
failure was defined as either the persistence ofCandida in the bloodstream
despite 3 days of antifungal therapy or development of breakthrough fun-
gemia while receiving azole antifungal agents for 3 days (21). Previous use
of azole antifungal agents was defined as administration within 3 months
prior to the onset of fungemia. Immunosuppression was defined as either
the presence of neutropenia (500/mm3 absolute neutrophil count) or
use of immunosuppressive therapy at the time of onset of fungemia.
Clearance of fungemia was assessed at the end of therapy, and the out-
come of the patients (survival or death) was assessed 30 days after the first
positive blood culture result. This study was approved by the Institutional
Review Board of Chonnam National University Hospital (IRB CNUH-
2014-290). A waiver of the requirement for informed consent was granted
given the retrospective nature of the project. Patient information was
anonymized and deidentified prior to analysis, and no information that
could lead to patient identification was used.
Statistical analysis. Comparison of relative gene expression was per-
formed using the Mann-Whitney test. Data expressed as numbers or per-
centages were compared using the chi-squared or Fisher’s exact test. Re-
lationships between CDR1, MDR, and ERG11 gene expression were
examined using Spearman’s correlation coefficient. All statistical analyses
were performed using SPSS version 18.0 (SPSS, Chicago, IL), and aP value
of0.05 was considered to indicate significance.
RESULTS
Antifungal susceptibilities. Table 1 shows CDR1, MDR1, and
ERG11 expression levels,ERG11 andUPC2 sequences, and MLSTs
of 35 clinical isolates of C. tropicalis. Of the 35 isolates, 9 (isolates
1 to 9) were determined to be FNS, including 6 fluconazole-resis-
tant (MIC, 8 g/ml) isolates and 3 fluconazole-susceptible
dose-dependent (SDD; MIC, 4 g/ml) isolates by the 24-h CLSI
method, while 12 (isolates 10 to 21) were FLS (MIC, 1 to 2g/ml)
isolates and 14 (isolates 22 to 35) were control (MIC, 0.125 to 0.5
g/ml) isolates. Of the nine FNS isolates, three were resistant to
voriconazole (voriconazole MIC, 1 g/ml), and the remaining
six exhibited dose-dependent susceptibility (SDD voriconazole
MIC, 0.25 to 0.5 g/ml) to voriconazole. However, 11 of 12 FLS
isolates and all 14 control isolates were susceptible to voricona-
zole. Fluconazole and voriconazole MICs obtained by Vitek-2
yeast susceptibility testing were 1-fold lower than those deter-
mined by the CLSI method, but the essential agreements (within
one dilution) of the CLSI for both fluconazole and voriconazole
testing were 97%. Itraconazole MICs for FNS, FLS, and control
isolates ranged from 0.5 to 2g/ml, 0.125 to 0.5g/ml, and 0.03 to
0.25 g/ml, respectively, and posaconazole MICs ranged from
0.25 to 1 g/ml, 0.06 to 1 g/ml, and 0.03 to 0.25 g/ml, respec-
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TABLE 1 Molecular characterization of 35 clinical isolates of Candida tropicalis
Isolate (patient) no. Source
Isolation
(yr)
Antifungal agent MICa (g/ml)
Gene expressionb Amino acid substitution(s)c
MLSTd
(DST)
FLU VOR
ITR
(CLSI)
POS
(CLSI)CLSI Vitek 2 CLSI Vitek 2 CDR1 MDR1 ERG11 Erg11p Upc2p
Fluconazole
nonsusceptible
1 Blood 2013 32 64 0.5 0.25 1 0.5 13.9 23.3 6.6 None A251T, Q289L 232
2 Blood 2008 16 8 1 0.5 2 0.5 16.2 10.5 23.1 None A297S,T393I,
(301-304),
Q320QPP
399
3 Blood 2009 16 4 0.5 0.25 1 0.25 49.2 3.8 24.8 None None 169
4 Blood 2003 8 8 0.5 0.25 1 0.25 5.6 17 75.6 None A251T, G392E 395
5 Blood 2007 4 4 0.5 0.25 1 0.25 11.6 11.8 28.4 L333I G392E 398
6 Blood 2011 4 2 0.25 0.12 1 0.5 8.1 18.1 56.7 None A251T, Q289L,
G392E
402
7 Ear pus 2006 64 64 2 1 2 1 5.9 27.1 27.6 G464S A251T, Q289L 396
8 Urine 2012 16 8 2 0.5 1 0.25 85.5 2.2 25.8 None A251T, Q289L,
L343F
188
9 Urine 2012 4 2 0.25 0.12 0.5 0.25 13.3 12.3 64 None A251T, Q289L,
G392E
404
Fluconazole less
susceptible
10 Blood 2013 2 2 0.03 0.12 0.5 0.06 41.8 30.4 5.2 None S187L 392
11 Blood 2006 2 1 0.125 0.12 0.25 0.125 7.3 9.5 14.5 None G392E 401
12 Blood 2012 2 1 0.125 0.12 0.125 0.25 4.7 9.1 8.5 G464S A251T, Q289L,
G392E
393
13 Blood 2012 2 1 0.03 0.12 0.5 0.25 3.9 10.6 3.1 None A251T, Q289L,
G392E
405
14 Blood 2012 1 1 0.25 0.12 0.5 1 24.4 13.5 2.9 None A251T, Q289L 232
15 Blood 2007 1 1 0.125 0.12 0.5 0.125 17.7 14.6 8 None A251T, Q289L 232
16 Blood 2013 1 1 0.06 0.12 0.125 0.25 15.7 28 28.7 None A251T, Q289L,
G392E
395
17 Blood 2013 1 1 0.06 0.12 0.5 0.25 4.3 15.7 16.5 None A251T, Q289L,
G392E
359
18 Blood 2012 1 1 0.06 0.12 0.25 0.125 18.5 12.2 6.9 None G392E 394
19 Blood 2006 1 1 0.06 0.12 0.5 0.125 10.2 17.2 16 None A251T, Q289L 400
20 Nasal
swab
2012 2 2 0.125 0.12 0.5 0.25 9.1 13.6 15.7 K344N,
V362 M
None 403
21 Urine 2012 2 1 0.06 0.12 0.5 0.25 5.6 10.2 5.7 None A251T, Q289L 232
Fluconazole
susceptible
(control)
22 Blood 2012 0.125 1 0.03 0.12 0.03 0.03 6.4 15.5 7.8 None G392E 448
23 Blood 2012 0.25 1 0.06 0.12 0.25 0.25 1.7 0.3 0.3 None A251T, Q289L,
S702L
385
24 Blood 2013 0.25 1 0.03 0.12 0.03 0.03 2.1 9.5 4.6 None A251T, Q289L,
G392E
395
25 Blood 2012 0.5 1 0.03 0.12 0.06 0.06 0.2 0.8 0.8 None None 417
26 Blood 2012 0.25 1 0.03 0.12 0.125 0.125 1.3 3.1 2.6 None None 401
27 Blood 2012 0.25 1 0.03 0.12 0.125 0.06 0.5 0.5 0.5 None None 401
28 Blood 2012 0.25 1 0.03 0.12 0.06 0.03 0.2 0.5 0.5 None None 110
29 Blood 2012 0.125 1 0.06 0.12 0.125 0.125 2.1 4.5 16.6 None None 426
30 Blood 2012 0.125 1 0.03 0.12 0.25 0.125 0.7 9.1 10 None A251T, Q289L 400
31 Blood 2013 0.125 1 0.03 0.12 0.06 0.03 1.4 0.9 3.9 None A251T, A263T NAe
32 Blood 2012 0.25 1 0.06 0.12 0.25 0.06 0.5 0.5 2 None A251T, Q289L 232
33 Blood 2012 0.125 1 0.03 0.12 0.06 0.06 0.6 0.5 0.1 None A251T, Q289L 124
34 Blood 2012 0.125 1 0.03 0.12 0.125 0.03 8.4 17.4 17.8 None A251T, Q289L,
G392E
395
35 Blood 2012 0.125 1 0.03 0.12 0.06 0.03 2.5 8.4 0.2 None A251T, Q289L,
G392E
431
a Antifungal MICs were determined by the 24-h CLSI M27-A3 broth microdilution method and the Vitek 2 yeast susceptibility system (AST-YS07; bioMérieux, Marcy L’Etoile,
France). ITR, itraconazole; FLU, fluconazole; POS, posaconazole; VOR, voriconazole.
b Quantification was performed using real-time RT-PCR. Values are averages from three independent experiments and represent increases in gene expression levels relative to the
mean expression levels in 14 control strains (isolates 22 to 35) with fluconazole MICs of 0.125 to 0.5 g/ml (set to 1.0).
c Homozygote alleles are underlined, while heterozygote alleles are not underlined.
d By multilocus strain typing (MLST), each strain was characterized as a diploid sequence type (DST) using the combination of the genotypes of the six genes (ICL1, MDR1, SAPT2,
SAPT4, XYR1, and ZWF1a) in the MLST database (http://pubmlst.org/).
e NA, MLST data not available. The genotypes of five genes, ICL1, MDR1, SAPT2, XYR1, and ZWF1a, were 1, 110, 39, 3, and 7, respectively, but the genotype of SAPT4 was not
obtained due to repeated sequencing failures.
Azole Resistance in Candida tropicalis
June 2016 Volume 60 Number 6 aac.asm.org 3655Antimicrobial Agents and Chemotherapy
tively. When applying species-specific ECVs, eight (all FNS) and
17 (9 FNS, 7 FLS, and 1 control) isolates of the 35 were categorized
as non-wild-type isolates for itraconazole (0.5 g/ml) and po-
saconazole (0.125 g/ml), respectively. The MIC ranges of am-
photericin B, anidulafungin, and micafungin for all 35 isolates
were 0.25 to 1 g/ml (all, wild-type), 0.03 to 0.125 g/ml (all,
susceptible), and 0.03 to 0.125 g/ml (all, susceptible), respec-
tively, by the CLSI method.
Expression of CDR1,MDR1, and ERG11. Using quantitative
RT-PCR, most control strains exhibited basal levels of CDR1,
MDR1, or ERG11 expression, with some fluctuations, but there
were two outliers (isolates 22 and 34) that showed overexpression
of both CDR1 (5-fold compared with the mean of all controls)
and MDR1 (15-fold compared with the mean of all controls)
(Fig. 1). Nine FNS isolates had 23.3-, 14.0-, and 37.0-fold higher
mean expression levels of the CDR1, MDR1, and ERG11 genes
than the 14 control isolates (P values of 0.0003, 0.0073, and 0.0002,
respectively). In addition, 12 FLS isolates also had 13.6-, 15.4-, and
11.0-fold higher expression levels of CDR1, MDR1, and ERG11
genes than control isolates (P values of 0.0001, 0.0011, and 0.0193,
respectively). There were no differences in the mean expression
levels of CDR1 or MDR1 between FNS and FLS isolates, but the
mean ERG11 expression levels were significantly (3.4-fold) higher
in FNS isolates (P  0.004). Moreover, ERG11 overexpression
(20-fold compared with controls) was more frequent in FNS
than FLS isolates (FNS versus FLS, 8/9 versus 1/12; P  0.0001).
According to Spearman’s correlation analysis, there was no signif-
icant correlation between CDR1 and MDR1 expression when all
35 isolates were assessed (r2 0.0159, P 0.4698); however, there
was a significant correlation betweenCDR1 andMDR1 expression
when 12 FLS isolates were assessed (r2  0.4871, P  0.0116),
while the expression of CDR1 was negatively correlated with that
of MDR1 when 9 FNS isolates were assessed (r2  0.5878, P 
0.0159) (Fig. 2). Also, there was no significant correlation between
ERG11 and CDR1 or MDR1 for all FNS and FLS isolates.
Amino acid substitutions in Erg11p and Upc2p. The ERG11
sequence analysis revealed that only 4 (two each of FNS and FLS)
of 35 isolates of C. tropicalis exhibited amino acid substitutions in
Erg11p. Homozygous L333I (isolate 5) and G464S (isolate 7) sub-
stitutions were present in two FNS isolates, while heterozygous
G464S (isolate 12) and both K344N and V362M (isolate 20) sub-
stitutions were detected in two FLS isolates.
By UPC2 gene sequencing, one to four amino acid substitu-
tions were found in 28 isolates, comprising 8 FNS, 11 FLS, and 9
control isolates. Notably, a BSI isolate (isolate 2), which showed
23.1-fold overexpression of ERG11 and a fluconazole MIC of 16
g/ml, exhibited the following heterozygous amino acid substitu-
tions: deletion of four amino acids, AQSP, at residues 301 to 304
(301-304) and insertion of two proline residues at amino acid
position 320 (Q320PPQ), in addition to A297S and T393I. Also,
seven distinct amino acid substitutions in UPC2 (S187L, A251T,
A263T, Q289L, L343F, G392E, and S702L) were found in 27 iso-
FIG 1 Relative expression levels of CDR1, MDR1, and ERG11 in 9 fluconazole-nonsusceptible isolates (FNS; MIC,4 g/ml), 12 fluconazole-less-susceptible
isolates (FLS; MIC, 1 to 2 g/ml), and 14 control strains (control; MIC, 0.125 to 0.5 g/ml) of Candida tropicalis. The relative expression level of each gene is
calculated relative to the means from 14 control strains, which was set to 1.0. Filled circles represent individual isolates of C. tropicalis; horizontal bars show the
mean gene expression levels of each group. *, P 0.05; **, P 0.01; ***, P 0.001.
FIG 2 Correlation between CDR1 and MDR1 expression in clinical isolates of C. tropicalis. (A) No significant correlation between CDR1 and MDR1 expression
was observed when all 35 isolates were assessed. However, the expression level of CDR1 showed a negative correlation with that of MDR1 when 9 fluconazole-
nonsusceptible isolates were assessed (r2 0.5878, P 0.0159) (B) and a positive correlation with that of MDR1 when 12 fluconazole-less-susceptible isolates
were assessed (r2 0.4871, P 0.0116) (C).
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lates. Of the seven amino acid substitutions in Upc2p, three
(A251T, Q289L, and G392E) were present irrespective of MIC
distribution, and the homozygous variant of Q289L was found in
five (one FNS, one FLS, and three control) isolates. While two
amino acid substitutions (A263T and S702L) were detected only
in control strains, two amino acid substitutions, L343F and S187L,
were found in one FNS (isolate 8) isolate and one FLS (isolate 10)
isolate, respectively.
MLST analysis. By MLST, the nine FNS isolates were found to
have nine distinct DST types. Of the 35 total isolates, 24 isolates
yielded new (unpublished) allele numbers, and the following 18
new DSTs were identified: 359, 392-396, 398-405, 417, 426, 431,
and 448. Overall, all 35 isolates yielded 25 distinct DSTs, while 4
DSTs were shared by 14 isolates (40%): DST 232, DST 395, DST
400, and DST 401 were shared by five (one FNS, three FLS, and
one control) isolates, four (one FNS, one FLS, and two control)
isolates, two (one FLS and one control) isolates, and three (one
FLS and two control) isolates, respectively.
Clinical characteristics of fungemia. The clinical course and
antifungal therapy of the 16 patients with FNS (patients 1 to 6) and
FLS (patients 10 to 19) BSI isolates are summarized in Fig. 3 and 4,
respectively. All 16 fungemic patients (15 adult and 1 pediatric
patient) had severe underlying diseases. Three (50%) FNS and five
(50%) FLS BSI isolates were recovered from patients with malig-
nancy. Twelve patients were using central venous catheters at the
time of onset of fungemia, but the results of the catheter tip culture
were negative for C. tropicalis in all patients, with the exception of
one (patient 18). Of four patients with FNS isolates (patients 2, 3,
5, and 6) who received3 days of azole therapy, three (patients 2,
3, and 6) developed breakthrough fungemia during azole therapy.
Patient 2 developed breakthrough fungemia during intravenous
fluconazole therapy (200 mg/day) for 2 days. He had received
intravenous fluconazole therapy (200 mg/day) for 10 days, which
stopped 10 days before fungemia onset. Patients 3 and 6 developed
breakthrough fungemia while receiving oral itraconazole therapy
for 10 days (200 mg/day) and 16 days (100 mg/day), respectively.
All patients with FNS isolates had a fatal outcome except for one,
patient 5, whose isolate showed a fluconazole MIC of 4g/ml and
FIG 3 Treatment regimens, fluconazole MICs of C. tropicalis isolates, and outcomes of six fungemia patients (patients 1 to 6) with fluconazole-nonsusceptible
(fluconazole MIC,4g/ml) isolates of C. tropicalis (isolates 1 to 6). Table 1 provides detailed information on each isolate. Previous antifungal exposure within
3 months was identified in all six patients with FNS isolates. Three patients (patients 2, 3, and 6) developed breakthrough fungemia during azole therapy. AMB,
amphotericin B; FLU, fluconazole; IST, immunosuppressive therapy at the time of onset of fungemia; ITR, itraconazole; CAS, caspofungin; F, female; M, male.
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who improved after 8 days of intravenous fluconazole (200 mg/
day).
Of the 10 patients with FLS isolates, 7 (patients 10, 11, 13, 15,
16, 17, and 19) received azole therapy. Blood cultures became
negative after intravenous fluconazole therapy in three patients
(400 mg/day for 16 days in patient 10, 400 mg/day for 6 days and
then changed to 100 mg for 2 days in patient 13, and 400 mg/day
for 9 days in patient 16). However, 4 (57%) showed azole thera-
peutic failure: one patient (patient 19) developed breakthrough
fungemia during oral itraconazole therapy (30 mg/day, 19 days),
and the remaining three patients (patients 11, 15, and 17) showed
persistent candidemia despite 3 days of azole therapy. Patients 11
and 15 received 32 days (200 to 400 mg/day) and 13 days (400
mg/day) of intravenous fluconazole therapy, respectively, and
both patients completely recovered, but patient 17 died after 15
days of intravenous fluconazole therapy (100 mg/day).
Overall, the rate of azole therapeutic failure was similar in patients
with FNS and FLS isolates (FNS versus FLS, 3/4 [75%] versus 4/7
[57%], respectively). Regarding other clinical characteristics of C.
tropicalis fungemia, FNS BSI isolates were more frequently iso-
lated from patients with immunosuppression (presence of neu-
tropenia or use of immunosuppressive therapy) than FLS BSI iso-
lates (6/6 and 3/10, respectively; P  0.011). In addition, FNS
isolates were more frequently associated with previous use of azole
agents than FLS isolates (6/6 or 100% versus 3/10 or 30%; P 
0.011). FNS isolates from fungemic patients were more frequently
associated with a fatal outcome (FNS versus FLS, 4/6 or 67% ver-
sus 4/10 or 40%, respectively) and uncleared fungemia (4/6 or
67% versus 4/10 or 40%, respectively) than FLS isolates, although
the difference was not significant.
DISCUSSION
The upregulation of CDR1 and MDR1, which encode efflux
pumps, has been reported to contribute to the azole resistance of
clinical isolates of C. albicans or C. glabrata (6, 22), and Barchiesi
et al. revealed the upregulation of CDR1 and MDR1 in an experi-
mentally induced fluconazole-resistant C. tropicalis strain (11).
However, Jiang et al. reported that ERG11 expression levels of 31
azole-resistant isolates were higher than those of 21 azole-suscep-
tible isolates, but the CDR1 and MDR1 expression levels were not
significantly different (8). In contrast to the four studies of azole
resistance mechanisms involving only one or two isolates of C.
tropicalis (7, 9–11), Jiang et al. investigated 52 clinical isolates ofC.
tropicalis from sputum, urine, or stool cultures (8). However, we
found that almost all (19/21) azole-susceptible isolates tested in
that study had fluconazole MICs of 1 g/ml; therefore, these
would have been classified as FLS in the present study. In the
present study, there were no differences in the mean expression
levels of CDR1 or MDR1 between FNS and FLS isolates, but the
mean ERG11 expression levels were significantly (3.4-fold) higher
in FNS isolates, which is in agreement with Jiang et al. However,
compared with those of the 14 control strains (fluconazole MIC,
0.125 to 0.5 g/ml), both FNS and FLS isolates showed signifi-
cantly higher mean expression levels (10-fold) of CDR1 and
MDR, as well as ERG11.
Based on the unresolved problems related to the reproducibil-
ity of caspofungin MICs observed in multicenter evaluations, test-
ing caspofungin for in vitro susceptibility currently is not recom-
mended (23). Instead, testing anidulafungin or micafungin is
recommended. All 35 isolates in this study were susceptible to
both anidulafungin and micafungin by the CLSI method. All FNS
isolates were resistant or SDD to voriconazole, while almost all
FLS and all 14 control isolates were susceptible to voriconazole. In
addition, FNS isolates showed higher MICs for both itraconazole
FIG 4 Treatment regimens, fluconazole MICs of C. tropicalis isolates, and
outcomes of 10 fungemia patients (patients 10 to 19) with fluconazole-less-
susceptible (fluconazole MIC, 1 to 2g/ml) isolates of C. tropicalis (isolates 10
to 19). Table 1 provides detailed information on each isolate. Of seven patients
(patients 10, 11, 13, 15, 16, 17, and 19) who received azole therapy, one (patient
19) developed breakthrough fungemia and three (patients 11, 15, and 17)
showed persistent fungemia despite 3 days of azole therapy. AMB, amphoter-
icin B; FLU, fluconazole; IST, immunosuppressive therapy at the time of onset
of fungemia; ITR, itraconazole; F, female; M, male; synd., syndrome.
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and posaconazole than FLS or control isolates, and of the nine
FNS isolates, eight and nine were categorized as non-wild-type
isolates (i.e., exceeding the ECVs) for itraconazole and posacona-
zole, respectively.
In the present study, convergent overexpression of CDR1 and
MDR1 was observed among the FLS isolates as well as in two
control strains (isolates 22 and 34), but it was not observed among
the FNS isolates. These findings suggest that CDR1 and MDR1
expression patterns differ between the FNS and FLS or control
isolates and that the CDR1 or MDR1 genes are differentially ex-
pressed in FNS isolates. Notably, most FNS (89%) isolates showed
20-fold ERG11 overexpression compared with the controls,
which was significantly higher than that of the FLS isolates. The
study by Jiang et al. also indicated that C. tropicalis isolates resis-
tant to all three azole antifungals (fluconazole, itraconazole, and
voriconazole) had a higher level of ERG11 expression than did
isolates resistant to fluconazole or itraconazole only (8). These
results prompted us to speculate that induction of the efflux
pumps encoded by the MDR or CDR genes is the initial step in
increasing fluconazole MICs to 1 to 2g/ml (to FLS isolates) inC.
tropicalis, and that overexpression ofERG11 further contributes to
the development of fluconazole and voriconazole resistance in
FNS isolates.
The missense mutation (A393T) of ERG11, which might lead
to decreased binding affinity for azoles, was first documented in
an azole-resistant clinical isolate of C. tropicalis (7). Forastiero et
al. reported the G464S substitution in a fluconazole-resistant C.
tropicalis isolate (10), and we found the G464S substitution in two
isolates with fluconazole MICs of 64 and 2 g/ml, although
whether this substitution was responsible for the azole resistance
is unclear. Of the four ERG11 missense mutations (L333I, G464S,
K344N, and V362M) ofC. tropicalis isolates detected in this study,
only one change, G464S, was found to be located in three previ-
ously defined hot spot regions of C. albicans, corresponding to
amino acids 105 to 165, 266 to 287, and 405 to 488 (24). In the
study by Jiang et al., ERG11 missense mutations were found in 8
FNS (fluconazole MIC, 4 to 64 g/ml) and 4 FLS (fluconazole
MIC, 2 g/ml) isolates of C. tropicalis, but all 12 isolates showed
the same ERG11 missense mutation (Y132F and S145F) (8). On
the other hand, we did not find the Y132F and S145F substitutions
in our isolates. Because increased resistance of C. tropicalis to flu-
conazole and outbreaks of infection caused by fluconazole-resis-
tant C. tropicalis have been recognized in some hospitals (5, 25,
26), C. tropicalis isolates with the ERG11 mutation should be
genotyped to investigate the transmission of particular clones. Al-
though overexpression of ERG11 associated with missense muta-
tions has been described as the mechanism of azole resistance in
clinical isolates ofC. tropicalis (7, 8), in the present study, only two
FNS isolates harbored ERG11 mutations, suggesting that gene
overexpression, rather than ERG11 mutation, is the main mecha-
nism of azole resistance in C. tropicalis isolates from Korean hos-
pitals. However, the contribution of ERG11 mutations to the de-
velopment of fluconazole resistance remains a possibility, as no
changes in ERG11 were found in the 14 control isolates.
Gain-of-function mutations in UPC2 can lead to ERG11 over-
expression and contribute to fluconazole resistance in clinical C.
albicans isolates (12–14). This is, to our knowledge, the first de-
scription of UPC2 variations in fluconazole-resistant C. tropicalis
isolates. Of the nine FNS isolates, seven (isolates 1 and 4 to 9)
isolates exhibited one or more of the three amino acid substitu-
tions (A251T, Q289L, and G392E); however, all three were also
found in control isolates. Two fluconazole-resistant isolates (iso-
lates 2 and 8) harbored mutations, including A297S, T393I,301-
304, Q320PPQ, or L343F, which were not found in FLS or control
isolates, but whether these substitutions result in azole resistance
is unclear. Upc2 is involved in sensing the ergosterol level in the
cell through its C-terminal ligand-binding domain, which con-
tains a glycine-rich activation loop at the extreme C terminus (27).
Many gain-of function mutations in the C-terminal activation
loop of Upc2p (e.g., Y642F, A643T, A643V, A646V, G648D, or
G648S) have been reported to contribute to the fluconazole resis-
tance of clinical C. albicans (12–14). However, six amino acid
substitutions in Upc2p (A251T, Q289L, A297S, L343F, G392E,
and T393I) in FNS isolates in the present study are located up-
stream of the C-terminal ligand-binding domain of Upc2p iso-
lates (Fig. 5). Thus, these results suggest that mutations upstream
FIG 5 Amino acid substitutions in Upc2p known to confer azole resistance in C. albicans compared to those in C. tropicalis in this study. While many
gain-of-function mutations (e.g., Y642F, A643T, A643V, A646V, G648D, or G648S) in azole-resistant clinical isolates ofC. albicans are located in the C-terminal
activation loop of Upc2p, six amino acid substitutions in Upc2p in fluconazole-nonsusceptible isolates of C. tropicalis in the present study are located upstream
of the C-terminal ligand-binding domain of Upc2p.
Azole Resistance in Candida tropicalis
June 2016 Volume 60 Number 6 aac.asm.org 3659Antimicrobial Agents and Chemotherapy
of the C-terminal ligand-binding domain of Upc2p inC. tropicalis
do not individually lead to decreased susceptibility to azole
drugs, although further genome-wide transcriptional analyses
are needed.
Previous azole exposure is an important risk factor for funge-
mia caused by fluconazole-resistant Candida isolates (28). How-
ever, the azole resistance of some clinical isolates of C. tropicalis
may not be associated with previous exposure to azole agents (3).
In the present study, previous fluconazole exposure was identified
in all six fungemic patients with FNS isolates. These findings, to-
gether with the fact that all FNS isolates exhibited unique DST
types, suggest that C. tropicalis FNS isolates in Korea have arisen
sporadically due to selective pressure imposed by prior azole
therapy.
C. tropicalis fungemia caused by FNS and FLS strains is uncom-
mon in Korea (16). Among 565 C. tropicalis BSI isolates from
Korean surveillance cultures between 2003 and 2013, only 6
(1.1%) displayed fluconazole MIC values of 4 g/ml, and 10
(1.8%) displayed fluconazole MIC values of 1 to 2 g/ml by the
24-h CLSI method. This is, to our knowledge, the first report on
the molecular and clinical features of C. tropicalis FNS BSI isolates
in comparison with those of FLS BSI isolates. Compared with FLS
isolates, FNS BSI isolates were significantly more frequently asso-
ciated with previous azole exposure or immunosuppression.
However, there were no significant differences in the rates of azole
therapeutic failure (3/4 versus 4/7) or uncleared fungemia (4/6
versus 4/10). Alternatively, although only 30% (3/10) of FLS BSI
isolates were associated with previous azole exposure, two FLS
isolates were obtained from two patients receiving azole therapy
for C. tropicalis fungemia. This suggests that FLS isolates of C.
tropicalis can be generated during treatment of C. tropicalis funge-
mia. In addition, of seven fungemic patients with FLS isolates who
received3 days of azole therapy, four (57%) showed therapeutic
failure, suggesting that greater clinical attention should be paid to
C. tropicalis isolates with reduced susceptibility to fluconazole
(i.e., MIC of 1 to 2 g/ml).
In summary, by comparing FLS and control isolates, we clari-
fied the molecular and clinical features of FNSC. tropicalis clinical
isolates recovered from Korean hospitals. First, a few FNS and FLS
isolates showed amino acid substitutions in Erg11p, but most ex-
hibited overexpression of CDR1, MDR1, and ERG11 compared to
control isolates, and FNS isolates showed greater ERG11 overex-
pression than FLS or control isolates. This suggests that overex-
pression of all three genes contributes to the development of flu-
conazole and voriconazole resistance in FNS isolates from Korean
hospitals. Second, amino acid substitutions in Upc2p were fre-
quently found among FNS, FLS, and even control isolates, but
none were likely to be located in the C-terminal activation loop of
Upc2p, suggesting that they do not contribute to the constitutive
activation of Upc2p in these C. tropicalis isolates. Third, FNS BSI
isolates were found more frequently in patients with immunosup-
pression or those with previous azole exposure than FLS isolates,
but some FLS BSI isolates can be obtained during therapy for
fungemia and are associated with azole therapeutic failure. There-
fore, further investigation is needed to determine the mechanisms
causing ERG11 expression and the clinical and molecular conse-
quences of the stepwise changes that result in the transformation
of FLS to FNS isolates of C. tropicalis.
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